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Abstract 
The association between diabetes and stroke is well established. Recent large scale, international 
population studies suggest that diabetes is one of the most important modifiable risk factors for 
cerebrovascular disease. Despite this, we still have a relative paucity of evidence around the management 
of diabetes in stroke. The landscape is evolving and recent studies are helping establish best practice and 
suggesting new therapeutic opportunities. It is possible to develop a practical and clinical synthesis of the 
evidence around managing diabetes in adult patients with stroke and cerebrovascular disease, based on 
large trials, systematic reviews and guidelines, and focussing on the scenarios most often encountered in 
clinical practice. It is also important to recognise that there are common situations where robust evidence 
is lacking, but practical guidance for clinicians can be suggested. 
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Key points  
• Diabetes is a risk factor for all forms of stroke disease 
• Hyperglycaemia in the acute phase after stroke is not all caused by diabetes, but all cases should be 
investigated for the possibility of underlying diabetes 
• Aggressive management of hyperglycaemia in acute stroke is not supported by evidence from 
randomised trials, and risks causing harm secondary to hypoglycaemia  
• In a person living with diabetes and stroke, the management of vascular risk factors, including 
blood pressure, lipid lowering and appropriate antithrombotic therapy, is just as important as 
managing glycaemia.  
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Introduction 
Observational epidemiology suggests that diabetes is a risk factor for all stages of the stroke journey, from 
cerebrovascular disease found incidentally on neuro-imaging, through to incident acute stroke and its 
longer-term recovery.  
For acute stroke, meta-analysis of prospective studies of individuals with diabetes and no history of 
vascular disease, indicates adjusted hazard ratios (HR) of 2.27 (95%CI 1.95-2.65) for ischaemic stroke and 
HR 1.84 (95%CI 1.59-2.13) for haemorrhagic stroke.(1) This increased risk is independent of traditional 
cardiovascular risk factors.(1) International case-control data estimates an Odds Ratio (OR) of 1.16 (95%CI 
1.05-1.30) for diabetes and risk of any first stroke event,(2) giving a population attributable risk of 3.9% 
(95%CI 1.9-7.6).(2)  Risks are elevated in all common forms of diabetes and in all stroke subtypes. Large 
population studies tend to focus on people with type 2 diabetes, but UK Primary Care data identified a HR 
for stroke of 3.7 in men and 4.8 in women with type 1 diabetes over seven years of follow-up.(3) People 
with Type 1 diabetes are also at higher risk of developing an intracerebral haemorrhage (RR 1.74 95% CI 
1.38-2.21) and of dying as a consequence (RR 1.35 95%CI 1.01-1.70).(4) 
Similarly, individuals presenting with acute stroke are more likely to have diabetes. Meta-analysis 
of 39 studies of inpatients diagnosed with stroke found an estimated prevalence of diabetes of 28% (95%CI 
26-31%), although the authors highlight significant heterogeneity in diagnostic approaches.(5) 
For those who experience stroke, the presence of diabetes or abnormal glycaemic status is 
associated with poor outcomes. A new diagnosis of diabetes made at time of presentation with acute 
stroke has been associated with poorer functional outcomes at one year in both ischaemic (OR 2.58; 95%CI 
1,95-3.43)(6) and haemorrhagic stroke (OR 1.93; 95%CI 1.10-3.38).(7) Finnish observational data identified 
a five-year survival of only 58% in a cohort of people with type 1 diabetes experiencing incident stroke, with 
mortality associated with worsening renal function.(8)   
Mechanistic studies suggest that hyperglycaemia can worsen ischaemic neuronal injury. However, 
the pathological effect of diabetes on the cerebral vasculature is not limited to clinically overt stroke. 
Cerebral small vessel disease (cSVD) is increasingly recognised as a risk factor for stroke and vascular 
dementia, with diabetes considered an important potentially modifiable risk factor.(9) Recent Mendelian 
randomisation data suggests a causal association between Type 2 diabetes and cSVD.(10)  Diabetes may 
potentiate and/or moderate neurological damage, and diabetes is associated with an elevated risk of 
undifferentiated dementia, before a stroke event (OR 1.90, 95%CI 1.25-2.88) and afterwards (HR 1.53, 
95%CI 1.18-1.98).(11) 
 
Acute Stroke 
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Hyperglycaemia in acute stroke 
A large proportion of stroke events occur in people living with diabetes.  Larger still is the proportion of 
people with an acute stroke that have abnormal glycaemia following a stroke event. Immediate post-stroke 
hyperglycaemia is estimated to affect 42.6% (95%CI 40.7-44.5%) of admissions, with a further 19.4% 
developing hyperglycaemia within 48-hours of admission.(12) Not all of these cases have diabetes, 
although hyperglycaemia in hospitalised patients is a recognised predictor of developing type 2 diabetes.  
Secondary analysis of data from the Glucose Insulin in Stroke Trial found 42% of those with hyperglycaemia 
at the time of acute stroke had a normal glucose tolerance at three month follow-up and 21% had diabetes 
mellitus.(13) Normal plasma glucose at the time of acute stroke does not exclude abnormalities in glucose 
metabolism, and up to a third of these individuals may have impaired glucose tolerance or abnormal 
glycosylated haemoglobin levels on formal testing.(14) The presence of admission hyperglycaemia with 
elevated glycosylated haemoglobin levels provided a positive predictive value of 80% and negative 
predictive value of 96% for diabetes at three months.(13) 
Any form of abnormal glycaemia seems to have an adverse prognostic effect and diabetes status or 
glucose feature in most acute stroke risk stratification tools.(15) Hyperglycaemia within the first 48 hours 
increases the risk of a poorer functional outcome by 12.9% (95%CI 9.2-16.7% ).(12) Subjects with elevated 
plasma glucose levels are at a 1.5-fold higher risk of mortality over three years of follow-up.(16) The 
mechanisms which account for this worsening of outcomes associated with hyperglycaemia have not been 
fully established.(17)  
Glycaemic control in acute stroke 
Given that abnormal glycaemia is common and associated with poor outcomes, it would seem intuitive that 
we should intervene to normalise blood glucose concentrations. The most recent Cochrane Review on 
intensive glycaemic control identified 11 randomised trials with 1583 participants.(18) Maintaining serum 
glucose levels within normal range (defined as 4 to 7.5 mmol/L) in the first 24 hours after acute ischaemic 
stroke was not associated with any differences with respect to death, dependency or neurological 
deficit.(18) Conversely, trying to achieve normoglycaemia in the acute period is not necessarily a benign 
intervention. The review reported a number needed to harm of only nine for symptomatic 
hypoglycaemia.(18)  
This lack of evidence to support acute treatment is reflected in guidelines. The European Stroke 
Organisation Guidance including published data to July 2015, states that current evidence does not 
demonstrate any significant benefit of tight glycaemic control using intravenous (IV) insulin in acute stroke 
on functional outcomes or survival.(19) However, the authors highlight that this conclusion is based on low 
quality evidence with significant heterogeneity in the included trials with respect to selection bias, different 
target glucose levels and different control interventions.(19) There is discordance between the two UK 
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guideline bodies on the approach to management of hyperglycaemia in acute stroke. The Scottish 
Intercollegiate Guidelines Network state:  
“routine use of insulin regimens to lower blood glucose in patients with moderate hyperglycaemia 
after acute stroke is not recommended…….patients with hyperglycaemia should be formally 
assessed to exclude or confirm a diagnosis of impaired glucose tolerance or diabetes”(20)  
Whereas the National Institute for Health and Care Excellence Guidance states: 
 “People with acute stroke should be treated to maintain a blood glucose concentration between 4 
and 11 mmol/litre.”(21) 
However, both guidelines emphasise that the management of those with an established diagnosis of 
diabetes should follow usual management protocols, including administration of essential insulin for people 
with type 1 diabetes.   
The Stroke Hyperglycaemia Insulin Network Effort (SHINE) trial seeks to address the uncertainties in current 
practice around how best to manage hyperglycaemia in acute stroke.(22) The trial recruited 80% of 
participants with known type 2 diabetes, and initial results suggest no improvement in functional outcomes 
(p=0.55) when using intensive continuous IV insulin therapy (target blood sugar 80-130mg/dL), compared 
to an approach described as ‘Standard sliding scale therapy’ but which involved administration of 
subcutaneous insulin every six hours to a target of <10.0 mmol/L.(23) The early results also found an 
increased risk of severe hypoglycaemia in the intensive treatment group (2.6% versus 0%).(23) 
Thrombolysis and glycaemic control 
The association between hyperglycaemia and adverse outcomes has been evaluated among stroke patients 
receiving thrombolysis treatment using observational datasets. These have identified that both acute 
hyperglycaemia at hospital admission (>7.8 mmol/l) and chronic hyperglycaemia (plasma glycosylated 
haemoglobin HbA1c >48 mmol/mol) are associated with increased in-hospital mortality and length of 
stay.(24) These effects are magnified as admission glucose increases above 11.1 mmol/l and HbA1c 
increase above 64 mmol/mol.(24) Hyperglycaemia on admission is also associated with early-neurological 
deterioration in those treated with IV thrombolytic agents (OR 1.17, 95%CI 1.07-1.28 per 1mmol/L 
increase).(25)  
More recent data has focused on identifying those with impaired fasting glucose, rather than 
hyperglycaemia alone. This identifies that those with impaired fasting glucose are at higher risk of poorer 
functional outcomes than those with normal fasting glucose, adjusted common OR 2.77 (95%CI 1.54-
4.97).(26) Based on observational data, the initial licence for thrombolytic therapy in acute ischaemic 
stroke discouraged thrombolysis in those with diabetes and previous stroke.  With time and experience, it 
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is now recognised that while this group are at risk of poor outcomes, the risk is greater still if no treatment 
is given.   
At one time there was substantial anxiety about thrombolysis in people living with diabetes.  We now 
recognise that while this group, particularly people with poor glycaemic control, are at higher risk of 
complications from thrombolytic therapy, they are also at higher risk of poor outcomes from stroke per 
se.  Trial and registry data have consistently shown that overall, people living with diabetes benefit from 
intravenous thrombolysis given as per licence.  Whether the same arguments apply to mechanical 
thrombectomy procedures or thrombolysis given based on advanced imaging parameters remains to be 
seen.   
Feeding and fluids  
There is a lack of high quality evidence to guide fluid replacement in stroke.(27) For all patients, current 
practice guidance advocates any regime that allows volume replacement while avoiding iatrogenic hypo or 
hyperglycaemia.(20) This is based on extrapolation of data from the Glucose Insulin in Stroke (GIST-UK) trial 
which observed a fall in plasma glucose levels in the 24-hours after stroke when IV saline was administered 
exclusively.(28) 
Clinical guidelines have been co-produced by the Joint British Diabetes Societies for Inpatient Care with 
NHS Diabetes and the Primary Care Diabetes Society to help improve the inpatient management of people 
with stroke who have diabetes and require enteral feeding.(29) These recommend a target blood sugar of 
6-12 mmol/L during enteral feeding; minimising use of IV insulin; establishing a subcutaneous insulin 
regime or administration of glucose-lowering agents via an NG tube; administering insulin at start of a bolus 
feed regime; monitoring capillary glucose 4-6 hourly when feed running and hourly if feed is unexpectedly 
stopped.(29) 
Most hospitalised patients with stroke and diabetes will be older and more likely to be frail and at risk of 
polypharmacy. Where swallow is impaired, there is an increased risk of developing a hyperosmolar 
hyperglycaemic state (HHS). HHS is a serious, but uncommon complication of stroke in people living with 
diabetes. There is a lack of empirical data around HHS in acute stroke. Treatment is the same as in other 
cases of HHS and prevention is key with careful monitoring of fluid balance and electrolytes. 
Pragmatic guidance  
Clinicians working in stroke should be mindful of the importance of glycaemic state. Blood glucose should 
be checked in every suspected stroke to exclude neuroglycopenia. It would seem reasonable to also check 
HbA1C. Where stroke is complicated by hyperglycaemia, aggressive blood glucose should be avoided and 
intervention may only be needed where blood glucose is very high. For patients with diabetes who have 
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impaired swallow, establishing early nasogastric feeding and liaison with nutritional teams can prevent 
harmful fluctuations in glucose.  
Primary and secondary prevention of stroke  
General considerations 
The presence of diabetes is a risk factor for all stroke syndromes, including intracerebral haemorrhage and 
transient ischaemic attack (TIA). The guidance on primary and secondary prevention generally applies to all 
types of stroke, unless specified. There are few large RCTs that specifically target diabetes in stroke 
survivors and so the evidence base is generally extrapolated from stroke subgroups of prevention studies. 
Non-pharmacological approaches 
Non-pharmacological approaches involving patient education have long been accepted as key components 
of diabetic care and guidelines,(30) and are likely to be just as important in stroke survivors.  Educational 
approaches which included face-to-face methods, cognitive reframing and exercise content were the most 
likely to improve glycaemic control from meta-regression of 28 educational interventions.(31)  For the 
many stroke survivors with type 2 diabetes and obesity, engagement in weight management interventions 
may improve glycaemic control and other vascular risk factors.(32, 33)  Bariatric surgery is associated with 
reduced rates of myocardial infarction (HR 0.56 95%CI 0.34-0.93), but has not demonstrated specific 
benefits on stroke (HR 0.73 95%CI 0.41-1.30) based on data from Swedish intervention study data.(34) 
While dietary and exercise interventions are crucial, recommendations may need to be modified based on 
any physical and cognitive impairments resulting from the stroke.  
Medical management of hyperglycaemia  
In people with type 1 diabetes the administration of insulin therapy as a continuous subcutaneous infusion 
delivered via an insulin pump device is associated with more favourable HbA1c levels compared to multiple 
subcutaneous injections.(35) Observational data suggests that, over 6.8 years of follow-up, insulin pump 
treatment in people with type 1 diabetes is associated with lower risk of fatal cardiovascular disease 
(coronary heart disease or stroke) HR 0.58 95% CI 0.40-0.85, compared to multiple daily injections.(36)  
Analysis of the overweight subgroup of participants included in the UK Prospective Diabetes Study 
treated with Metformin identified macrovascular benefits from therapy,(37) a finding which continues to 
influence prescribing practice. The lack of significant reduction in stroke events or stroke mortality would 
not provide evidence against such treatment and metformin continues to be a first line treatment for many 
people with type 2 diabetes.  
Management algorithms for type 2 diabetes have been updated to reflect the newer agents which 
are now in routine clinical use.(30) The key antidiabetes drugs are summarised in Table 1. Pooled data from 
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published meta-analyses are included, summarising the effects of treatment using each agent on risk of 
stroke. It is noteworthy that many of these do not achieve statistical significance for stroke alone, but 
pooled primary outcomes or those for cardiovascular events often will.(38-42) One exception is in the 
meta-analyses of trials of pioglitazone which show statistical significance in stroke and recurrent stroke.(43, 
44) These analyses included the PROactive trial (PROspective pioglitAzone Clinical Trial in macroVascular 
Events 04), which showed a significant reduction in recurrent stroke with pioglitazone treatment, but no 
treatment effect for first stroke.(45)  
The Insulin Resistance Intervention after Stroke (IRIS) trial treated patients without a diagnosis of 
diabetes (but with evidence of insulin resistance) who had recently experienced a stroke or TIA with 
pioglitazone or placebo.(46) Pioglitazone treatment was associated with a lower risk of diabetes (HR 0.48 
95%CI 0.33-0.69), but higher risk of weight gain >4.5kg (52.2% vs 33.7%, p<0.001) and fracture requiring 
surgery or hospital admission (5.1% vs 3.2%, p=0.003).(46) Over five years follow-up treatment with 
pioglitazone was associated with a reduced risk of any stroke (HR 0.75 95%CI 0.60-0.94), with statistically 
significant effects on reducing ischaemic stroke (HR 0.72 95%CI 0.57-0.91), but not haemorrhagic stroke 
(HR 1.00 95%CI 0.50-2.00).(47)  The implications of IRIS for clinical practice are still debated. Pioglitazone 
for primary prevention has not entered clinical guidelines and is not routine in practice, as most consider 
the risk benefit ratio unfavourable. However, if the treatment could be targeted to those most at risk of 
stroke but at lesser risk of adverse effects then the intervention may achieve greater traction. This is not 
pure speculation, modelling studies based on IRIS data suggested a targeted approach may have net 
efficacy.(48, 49) 
In addition, data are presented on key Cardiovascular Outcome Trial (CVOT) findings with respect 
to stroke, available for new agents evaluating drug safety in those at high vascular risk or with established 
cardiovascular disease. In SUSTAIN-6 semaglutide significantly reduced stroke as a secondary endpoint, and 
the clinical applicability of this finding is uncertain at this point in time.(50)  
Network meta-analysis of new antidiabetic medications found no evidence of increased 
cardiovascular events.(51) One consideration is whether effects of treatment impact multiple other 
systems and that by reducing these risks, improvements in outcomes occur. For example, use of linked 
Scottish routine health data identified that treatment with dapagliflozin was associated with reduced 
HbA1c, systolic blood pressure (-4.32mmHg 95%CI -4.84 to -3.79) and body weight after three months of 
exposure.(52) 
Management of other risk factors 
The evidence with respect to risk factor management and direct effects on stroke risk has been more 
clearly established. Indeed in the patient with stroke and diabetes, attending to blood pressure and lipids 
may have greater effect on recurrence than treating glycaemia. Meta-regression analyses demonstrate that 
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for every 10mmHg reduction in systolic blood pressure, there is a reduced risk of stroke (RR 0.73 95%CI 
0.68-0.77).(53) Absolute risk reduction in stroke events among people with type 2 diabetes for blood 
pressure reduction is 4.06 (95% CI 2.53-5.40).(54) Cholesterol lowering for adults with diabetes is effective 
in reducing vascular mortality (RR 0.87 95%CI 0.76-1.00) and stroke events (RR 0.79 95%CI 0.67-0.93).(55) 
Adults with diabetes should have atrial fibrillation managed as it would among those without a diagnosis of 
diabetes, as a further important component of reducing risk of stroke.(56) Supporting people living with 
diabetes to reduce their risk factors is vital – those with type 1 diabetes who met no risk factor targets had 
a HR 12.03 (95% CI 7.66-18.85) for stroke over 10.4 years, compared to an HR 1.17 (95 CI 1.15-2.88) for 
those achieving all targets.(57) 
Pragmatic Guidance 
Diabetes often accompanies other recognised cardiovascular risk factors such as hypertension and 
dyslipidaemia. In many cases, optimal management of the person living with stroke and diabetes looks 
similar to management of stroke per se, for example in ischaemic stroke antihypertensive and potent statin 
therapy would routinely be given. However, given the increased risk associated with diabetes in 
combination with other risk factors, the thresholds for initiating treatment may be lower and the 
therapeutic targets may be more stringent albeit this is not a formal recommendation in UK stroke 
guidelines.  
Although stroke can occur at any age, it remains a disease predominantly seen in older adults. 
Guidelines based on evidence from middle aged populations with single diseases may not be applicable to 
frail, older adults with multimorbidity. This is particularly true in stroke, where frailty or pre-frailty is the 
norm.(58)   
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Table 1: Summary of antidiabetes drugs and stroke risk data 
Drug class Drug names Stroke risk from meta-
analyses of randomised 
controlled trial data   
Stroke risk from statistically 
significant Cardiovascular 
Outcome Trials (CVOT)  
Biguanides Metformin Meta-analysis of 13 trials 
Stroke RR 1.04 (0.73-1.48)(38)  
CVOT data not available 
Sulphonylureas Glibenclamide 
Gliclazide 
Glimepiride 
Glipizide 
Tolbutamide 
Meta-analysis of 23 trials 
Stroke OR 1.16 (0.81-1.66)(39) 
CVOT data not available 
DPP-4 inhibitors Alogliptin 
Linagliptin 
Saxagliptin 
Sitagliptin 
Vildagliptin 
Meta-analysis of 19 trials 
Stroke OR 0.64 (0.34-1.21)(40) 
All CVOT data neutral for 
major adverse cardiovascular 
events(59) 
Thiazolidinediones Pioglitazone Meta-analysis of 4 trials 
Stroke RR 0.81 (0.68-0.96)(43)  
Meta-analysis of 3 trials 
Recurrent stroke HR 0.68 
(0.50-0.92)(44) 
CVOT data not available 
SGLT-2 inhibitors Canagliflozin  
Dapagliflozin 
Empagliflozin  
Ertugliflozin 
Meta-analysis of 27 trials 
Stroke HR 0.84 (0.61-1.16)(41) 
EMPA-REG OUTCOME fatal 
and nonfatal stroke HR 1.18 
(0.89-1.56)(60) 
Sensitivity analysis including 
only cerebrovascular events 
on treatment or within 90 
days HR 1.08 (0.81-1.45)(60) 
CANVAS Program nonfatal 
stroke HR 1.93 (1.46-2.56)(61) 
DECLARE-TIMI 58 Ischaemic 
stroke HR 1.01 (0.84-1.21)(62) 
GLP-1 receptor 
agonists   
Albiglutide 
Dulaglutide 
Exenatide 
Meta-analysis of 77 trials 
Stroke RR 0.88 (0.76-1.02)(42) 
Harmony Outcomes fatal and 
nonfatal stroke HR 0.86 (0.66-
1.14)(63) 
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Liraglutide 
Lixisenatide 
Semaglutide 
LEADER fatal and nonfatal 
stroke HR 0.86 (0.71-1.06)(64) 
SUSTAIN-6 Nonfatal stroke HR 
0.61 (0.38-0.99)(50) 
 
Glossary 
95%CI – 95% confidence interval 
CANVAS Program – Canagliflozin Cardiovascular Assessment Study  
CI – contraindications  
CVOT – cardiovascular outcome trials  
DECLARE-TIMI 58 – Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction 58  
DKA – diabetic ketoacidosis 
DPP-4 inhibitors – Dipeptidylpeptidase-4 inhibitors  
EMPA-REG OUTCOME – Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients 
GLP-1 receptor agonists – Glucagon-like peptide-1 receptor agonists 
HbA1c – plasma glycosylated haemoglobin  
HR – hazard ratio 
IV – intravenous  
LEADER – Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results  
OR – odds ratio 
RCT – randomised controlled trial  
RR – risk ratio 
SGLT-2 inhibitors – Sodium-glucose co-transporter 2 inhibitors  
SUSTAIN-6 – Semaglutide in Subjects with Type 2 Diabetes 
TIA – transient ischaemic attack  
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